Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 5
2012 3
2013 4
2015 4
2016 5
2017 3
2018 3
2019 7
2020 3
2021 9
2022 7
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Brose MS, et al. Among authors: vaisman f. Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19. Cancer. 2022. PMID: 36259380 Free PMC article. Clinical Trial.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Among authors: vaisman f. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Capdevila J, et al. Among authors: vaisman f. Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23. Thyroid. 2024. PMID: 38062732 Free PMC article. Clinical Trial.
A new appraisal of iodine refractory thyroid cancer.
Vaisman F, Carvalho DP, Vaisman M. Vaisman F, et al. Endocr Relat Cancer. 2015 Dec;22(6):R301-10. doi: 10.1530/ERC-15-0300. Epub 2015 Aug 25. Endocr Relat Cancer. 2015. PMID: 26307020 Review.
Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C, Schneider R, Platonova T, Fridman M, Malzahn U, Mäder U, Vrachimis A, Bogdanova T, Krajewska J, Elisei R, Vaisman F, Mihailovic J, Costa G, Drozd V. Reiners C, et al. Among authors: vaisman f. Front Endocrinol (Lausanne). 2020 Jul 10;11:381. doi: 10.3389/fendo.2020.00381. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32754115 Free PMC article. Review.
60 results